Related Experiment Videos
V599EB-RAF is an oncogene in melanocytes
Claudia Wellbrock1, Lesley Ogilvie, Douglas Hedley
1Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, The Institute of Cancer Research, London, United Kingdom.
Cancer Research
|April 3, 2004
Summary
Oncogenic B-RAF drives early melanoma by activating MEK/ERK signaling. However, this pathway shows redundancy in RAS-transformed cells, impacting future melanoma therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- The V599E mutation in B-RAF is prevalent in human melanomas but also found in benign nevi, obscuring its oncogenic role.
- Understanding B-RAF's function in early melanoma development is crucial for targeted therapies.
Purpose of the Study:
- To investigate the role of oncogenic V599E B-RAF in the early stages of melanoma.
- To elucidate the signaling pathways and cellular consequences of V599E B-RAF expression in melanocytes.
Main Methods:
- Expression of V599E B-RAF in cultured melanocytes.
- Analysis of mitogen-activated protein kinase (MAPK) pathway signaling (MEK and ERK).
- Assessment of cell proliferation and tumorigenicity in vivo.
Main Results:
- V599E B-RAF induced constitutive MEK/ERK signaling, promoting growth independent of external stimuli.
- Cells expressing V599E B-RAF exhibited tumorigenicity in nude mice.
- B-RAF depletion did not inhibit MEK-ERK signaling or cell cycle progression in RAS-transformed melanocytes or human melanoma cells with oncogenic RAS, indicating pathway redundancy.
Conclusions:
- Oncogenic B-RAF acts as a potent driver in early melanoma via MEK/ERK signaling.
- RAS-mediated signaling bypasses the need for B-RAF in later-stage or RAS-driven melanoma.
- Therapeutic strategies targeting B-RAF may be less effective in melanomas with RAS pathway activation due to inherent redundancy.